Background -Several factors have been identified which improve nebulised aerosol delivery in vitro. One of these is the addition ofa spacer to the ventilator circuit which improves aerosol delivery from a jet nebuliser to a model lung by approximately 30%. The current study was designed to demonstrate whether similar improvements could be demonstrated in vivo. Methods -Ten patients (seven men) were studied during mechanical ventilation (Siemens Servo 900C) after open heart surgery. Aerosol was delivered using a Siemens Servo 945 nebuliser system (high setting) driving a System 22 Acorn jet nebuliser (Medic-Aid) containing 3 ml technetium-99m labeliled human serum albumin (9Tc-HSA (50 tg); activity in the first nebulisation, 90 MBq; in the second nebulisation, 185 MBq). Central and peripheral lung aerosol deposition and the time to complete deposition were measured using a gamma camera and compared when the nebuliser was connected to the inspiratory limb using a simple Tpiece or a 600 ml spacer. Results -The addition of the spacer increased total lung deposition (mean (SD) percentage initial nebuliser activity) from 2-2 (0-7)% to 3 (0.8)%. There was no difference in the time required to complete nebulisation (18-2 min v 18-3 min respectively for T-piece and spacer) or in the retention of activity in the nebuliser (46-2% v 47-1% respectively). Conclusions -The combination ofa spacer with a jet nebuliser increased lung deposition by 36% in mechanically ventilated patients and is a simple way of increasing drug deposition or reducing the amount of an expensive drug required for nebulisation. (Thorax 1995;50:50-53) 
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The administration of nebulised drug aerosols to mechanically ventilated patients is increasing in intensive therapy units. Several studies have shown in vivo pulmonary aerosol deposition to be poor, in the range 1-2-2-9%.1-3 In vitro methods investigating pulmonary deposition, using ventilator circuits and artificial lungs, have shown a number of ways in which aerosol delivery may be improved during mechanical ventilation"6 including changing the type of nebuliser or ventilator settings or increasing the volume of fill of the nebuliser.
The addition of a chamber to conserve aerosol formed by jet nebulisers during the expiratory phase of respiration for subsequent delivery during inspiration has been shown almost to double aerosol deposition in spontaneously breathing subjects.7 In vitro studies have shown that the addition of a similar chamber or spacer also improves delivery of aerosol from a jet nebuliser to a lung model by at least 25% during mechanical ventilation.56 This effect has not been shown in vivo. This study was therefore designed to determine whether the addition of a spacer to a jet nebuliser improves pulmonary deposition in mechanically ventilated patients.
Methods

PATIENT SELECTION
Ten patients (seven men, eight ex-smokers and two never smokers) were studied during mechanical ventilation after open heart surgery. The study was A Siemens Servo 945 nebuliser system (high setting) was used to administer a solution of technetium-99m labelled human serum althe bumin (99mTc-HSA 50 ,tg) in 3 ml saline using a System 22 Acorn jet nebuliser (Medic-Aid, Sussex, UK). In the first study the nebuliser was positioned via a T-piece in the inspiratory limb set 12 cm from the Y piece. In the second study a 600 ml spacer was included in the delivery system at the same distance (fig 1) . The order ofthese two studies was randomised. Thus, two studies of aerosol deposition were performed in each patient, with activities in the nebuliser of 90 MBq in study 1 and 185 MBq in study 2. Nebulisers were placed on the camera face before and after nebulisation. L T Study 2 was performed immediately after completion of study 1 using the same ventilator settings, experimental methods, and nebulisation equipment. Since the administration of aerosols via a jet nebuliser during mechanical ventilation requires inspiratory phase actuation, the volume of gas necessary to drive the nebuliser has to be taken into account when setting the tidal volume. The respiratory minute volume was therefore adjusted manually on the ventilator to compensate for the consequent rise in expired minute volume when the nebuliser is in use.
During nebulisation pulmonary deposition of 99mTc-HSA was measured continuously via the gamma camera (anterior projection) in 15 L T second frames. Following completion of nebulisation, anterior and posterior static scans of the lungs were taken, each over 300 second periods. The gamma camera was also used to measure activity in the T-piece, exhalation filter, and spacer after nebulisation. mastersizer. The aerosol was measured at the tip of the endotracheal tube; the conditions were otherwise the same with a humidifier operating in the circuit. The particle sizes were recorded as the mass median diameter and the span. The distribution of particles from a nebuliser have a gaussian distribution. The span is therefore defined as the ratio obtained by subtracting the 10th centile particle size diameter from the larger diameter of the 90th centile particle dimension and dividing by the size of the 50th centile particle.
Results
Patient details are given in table 1. All had undergone either cardiac valve replacement or coronary artery bypass graft surgery and were intubated with an 8 mm or 9 mm cuffed endotracheal tube.
The mass median diameter (gm) ± span of the aerosol without the spacer was 3 5 gim + 0 2 and with the spacer was 3 5 um+±0 1.
The pattern of radioaerosol distribution, expressed as percentage initial nebuliser activity, is given in ising the nebuliser position, changing the gas flow to the nebuliser, increasing the inspiratory fraction, reducing the respiratory rate or minute volume, increasing nebuliser fill, or reducing humidity.4 These in vitro measurements indicate possible ways of increasing delivery to patients but they cannot allow for the specifics of airway geometry and humidity, lung disease, or mucus secretion. Neither can they predict the site of deposition within the bronchial tree. Thus, in vivo studies are needed to quantify the amount deposited in the trachea, major airways, and "peripheral" lung. In vitro aerosol delivery will be greater than the in vivo lung deposition since the filter used in the model ventilator circuit captures all delivered aerosol particles and cannot quantify the proposition that would be exhaled or deposited in the major airways and the endotracheal tube. Other indirect techniques used in vivo may overestimate the delivery to the lungs and be misleading since the deposition within the patient may be in the trachea or major airways rather than the peripheral lung.8
Nebulised aerosol deposition in mechanically ventilated patients has previously been found to be between 1P2% and 2-9%,'-' which is not as efficient as deposition in spontaneously breathing subjects even though the nebuliser is usually only activated during lung inflation. As aerosol therapy may be of value in many patients requiring mechanical ventilation, it is important to establish why deposition is so poor and to design nebuliser systems which deliver therapeutic aerosols more efficiently. Observation of inspiratory phase activated jet nebulisers indicated that some aerosol produced towards the end of lung inflation did not reach the patient but was lost down the expiratory limb ofthe ventilator circuit. It therefore appeared possible that increasing the volume of the tubing between the nebuliser and the patient by the addition of a reservoir or spacer might conserve this wasted aerosol for delivery at the subsequent lung inflation. This has been shown in spontaneously breathing subjects with aerosol and metered dose inhalers.79"-" This effect was confirmed in vitro by studies using a 600 ml spacer5 and this volume was chosen for study in vivo because it approximates the tidal volume.
For these studies the System 22 Acorn nebuliser and Siemens 945 nebuliser activating system were chosen because they are commonly used on intensive care units and produce suitably sized particles, small enough to pass through the ventilator circuit and endotracheal tubing to reach the patient. The experimental protocol, involving two separate but sequential experiments in the same patient, was chosen because it is convenient and allows a paired comparison. Its validity and reproducibility have been reported previously.'
The results confirmed that total pulmonary deposition is consistent with values found in previous studies as is the percentage deposited in the endotracheal tube/trachea and retained in the nebuliser.3 Pulmonary deposition and ventilation were reduced in the left lung. This was most probably due to the opening of the pleura on the left side during the operative procedure. This would result in the greater degree ofcollapse ofthe left lung with the lower lobe expansion being most affected postoperatively. The results also showed that the improvement in aerosol delivery with a spacer obtained in vitro could be produced in vivo, and that aerosol delivery was significantly increased to all regions of the lung. This is an important observation as it illustrates the value of in vitro studies using lung models for predicting the effects of nebuliser or ventilator circuit modifications on aerosol delivery in vivo. The increase was associated with a reduction in aerosol entering the expiratory limb of the circuit and this is consistent with the way the spacer works. The observed improvement is modest and is unlikely to be of great clinical importance when used alone. However, when used in combination with other modifications -for example, increased volume of fluid in the nebuliser -it may make a useful contribution to an overall improvement in aerosol deposition. It was to be expected that the improvement in delivery with an aerosol reservoir would not be as great during volume cycled ventilation as in spontaneously breathing subjects, as in the former the nebuliser is inspiratory phase activated and a larger proportion of the aerosol is produced during lung inflation. Larger improvements would be predicted if the nebuliser was driven throughout the respiratory cycle, as happens with pressure cycled ventilation. It may also be that 600 ml is not the optimum spacer volume and further studies in this area would be useful.
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